Image Ingest

• Onclara™ can be deployed directly in pharma cloud environment (i.e, Microsoft Azure Foundry) for ingest
• CT scans can also be securely uploaded to Onclara™ Studio (cloud-hosted)
• Data transfer also supported by leading pharma/oncology CROs
• Handles baseline-only and all scans
• Secure, fully de-identified data pipeline with automatic quality control and self-correction

Predict and Analyze

• CT scan from all major hardware vendors are seamless harmonized and scans covering chest/abdomen/pelvic regions are stitched together
• Achieve superior survival prediction compared to RECIST with Onclara™ Evaluate
• Drivers of patient risk also determined (tumor burden, body composition, vasculature).
• Generates structured, standardized scores at both individual patient and cohort levels

Apply

• Enables more confident go/no-go decisionmaking in Phase IB and Phase II solid tumor trials
• Onclara™ AI models can also be used for effective comparison of treatment arms, prospective enrichment and patient stratification

Cohort-level analysis and Kaplan Meier curve

Patient-level analysis, tumor burden

Patient-level analysis, body composition

Order the Test

• Oncologist initiates an order for Onclara
• Evaluate or Onclara
• IO
• Routine clinical CT scans are securely retrieved and processed with no additional input or manual annotation required
• Predictions are returned to the ordering oncologist (PDF report or directly on oncology EMR)

AI-Driven Analysis

Sophisticated deep-learning AI models automatically extract clinically relevant imaging biomarkers:

• Tumor radiomic signature (intensity, texture, morphology)
• Multi-site tumor burden (volume and spatial distribution across affected organs)
• Vascular structure and morphology
• Advanced body composition metrics

Actionable Reporting

Within 24 hours, oncologists receive a comprehensive and intuitive report featuring:

• Onclara™ IO: High/low risk stratification for 12-month overall survival in PDL1-High mutation negative mNSCLC (just using a patient’s baseline/pre-treatment CT scan)
• Onclara™ Evaluate: Identification of the highest risk patients and presentation of a calibrated probability of the patient achieving 12 month overall survival (for mutation negative mNSCLC, PDL1-High/Low/Neg)